http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018247011-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f73ef3ceb255aeaffca551430b4cb4e0
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B30-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B30-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F19-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F19-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B15-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F19-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0208
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F19-22
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B30-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B15-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-112
filingDate 2016-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f46a7cd79e9449634596ffa1b0d9b5d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1d5afeff0f929067b2af5c43f489a04
publicationDate 2018-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2018247011-A1
titleOfInvention A method for cd4+ t-cell epitope prediction using antigen structure
abstract The present invention relates to novel methods of diagnosing, preventing, and treating diseases, disorders, and infections relating to T-cell response. The disclosed methods for predicting MHC class II epitopes that elicit CD4+ T-cell response are N based on the three-dimensional protein structure of an antigen of interest. Given such an antigen, structural properties of the protein taken from experimental and modeling data are used to compute an epitope likelihood score that characterizes the location of epitopes likely to elicit an immune response to CD4+ T-cells. The epitopes are then used to construct biomolecules, including peptides, which may be used to diagnose, prevent, and/or treat a number of diseases, disorders, and infections.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115458049-A
priorityDate 2015-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226427744
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226504276
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394558
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421272
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID338
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3429
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11583
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3604

Total number of triples: 42.